1. Academic Validation
  2. TRIM21-From Intracellular Immunity to Therapy

TRIM21-From Intracellular Immunity to Therapy

  • Front Immunol. 2019 Aug 28:10:2049. doi: 10.3389/fimmu.2019.02049.
Stian Foss 1 2 3 Maria Bottermann 4 Alexandra Jonsson 2 3 4 Inger Sandlie 1 2 Leo C James 4 Jan Terje Andersen 2 3
Affiliations

Affiliations

  • 1 Department of Biosciences, Centre for Immune Regulation, University of Oslo, Oslo, Norway.
  • 2 Department of Immunology, Centre for Immune Regulation, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway.
  • 3 Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway.
  • 4 Laboratory of Molecular Biology, Protein and Nucleic Acid Chemistry Division, Medical Research Council, Cambridge, United Kingdom.
Abstract

Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin Ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell membrane. Upon engagement of the Fc of antibodies bound to viruses, TRIM21 triggers a coordinated effector and signaling response that prevents viral replication while at the same time inducing an anti-viral cellular state. This dual effector function is tightly regulated by auto-ubiquitination and phosphorylation. Therapeutically, TRIM21 has been shown to be detrimental in adenovirus based gene therapy, while it may be favorably utilized to prevent tau aggregation in neurodegenerative disorders. In addition, TRIM21 may synergize with the Complement System to block viral replication as well as transgene expression. TRIM21 can also be utilized as a research tool to deplete specific proteins in cells and zebrafish embryos. Here, we review our current biological understanding of TRIM21 in light of its versatile functions.

Keywords

TRIM21; antibody; gene therapy; infection; virus.

Figures